ASG-15ME is a Study of Escalating Doses of AGS15E Given as Monotherapy in Subjects With Metastatic Urothelial Cancer
This study is ongoing, but not recruiting participants.
First Posted: October 16, 2013
Last Update Posted: November 16, 2017
Seattle Genetics, Inc.
Information provided by (Responsible Party):
Astellas Pharma Inc ( Agensys, Inc. )
No Study Results Posted on ClinicalTrials.gov for this Study
|Study Status:||This study is ongoing, but not recruiting participants.|
|Estimated Study Completion Date:||January 2018|
|Estimated Primary Completion Date:||January 2018 (Final data collection date for primary outcome measure)|